Tissium, a French medical technology company focused on regenerative medicine, has announced the closing of a €60 million financing round comprising €30 million in equity and €30 million in debt. The Series D-2 funding will support the company’s geographic expansion into the United States market and accelerate its clinical trial programs.
The equity component was led by a previously undisclosed US-based family-owned institutional investor, marking the first participation of this prominent American family office in the company’s cap table. Existing shareholder Mérieux Développement, the investment arm of the Mérieux family, continued its backing alongside Cathay. The round also attracted participation from newly committed family offices and high net worth individuals, demonstrating sustained confidence in Tissium’s technology platform.
The financing brings Tissium’s cumulative funding to €200 million since its inception, positioning the company among Europe’s well-capitalized MedTech ventures. The dual equity-debt structure reflects confidence from both institutional and debt providers in the company’s path toward revenue generation.
Advancing commercial transition
Tissium has built its product portfolio around a proprietary biomorphic polymer platform designed to support tissue regeneration. The fresh capital injection comes as the company progresses from development into commercial operations, with particular focus on establishing its presence in the lucrative US healthcare market.
Christophe Bancel, commenting on the fundraising, stated: “We are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform.” This statement underscores Tissium’s dual strategy of commercializing current products while maintaining research momentum on next-generation offerings.
The allocation of funds reflects this dual focus, with resources directed toward both scaling operations in the United States and supporting clinical validation programs that will establish clinical efficacy across the company’s portfolio.
European MedTech funding momentum
Tissium’s successful fundraising contributes to a broader trend of significant capital deployment in European MedTech. The company’s ability to attract both established investors and new institutional participants from North America signals the growing recognition of European regenerative medicine capabilities on the international stage.
The involvement of US-based family offices in European MedTech financing indicates increasing cross-Atlantic investment activity, particularly for companies demonstrating clear pathways to revenue and market expansion. Tissium’s €200 million funding trajectory places it within a select group of European MedTech companies that have secured deep institutional backing necessary for global commercialization.
The company’s focus on clinical validation and US market entry represents a common trajectory for venture-backed European medical technology firms seeking to capitalize on both innovation advantages and access to larger addressable markets outside the continent.